Stockscreener 앱 받기
13.88
2.66%
-0.38
시간 외 거래:
13.88
Bioventus Inc 주식(BVS)의 최신 뉴스
Can Bioventus (NASDAQ:BVS) Keep Its Momentum Going? - Kalkine Media
BVS Maintains Buy Rating by Canaccord Genuity -- Price Target Ra - GuruFocus
BVS Reiterated by Cantor Fitzgerald -- Price Target Maintained a - GuruFocus
Bioventus (NASDAQ:BVS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
Bioventus' (BVS) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
(BVS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bioventus (BVS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Dimensional Fund Advisors LP Increases Position in Bioventus Inc. $BVS - MarketBeat
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings - Yahoo Finance
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance - Yahoo Finance
Bioventus (NASDAQ:BVS) Gains Attention After Strong Quarterly Update - Kalkine Media
Sei Investments Co. Boosts Holdings in Bioventus Inc. $BVS - MarketBeat
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Bioventus (BVS) Is Up 6.1% After Reaffirming 2026 Sales Outlook And Strong Q2 Earnings Jump - Sahm
Bioventus Inc. (BVS) Stock Analysis: Healthcare Innovator With 5.87% Upside Potential - DirectorsTalk Interviews
Bioventus Inc (BVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bioventus Inc (BVS) Stock News Today - TradingKey
Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance
Bioventus Inc. $BVS Shares Sold by Renaissance Technologies LLC - MarketBeat
Latham & Watkins Advises Bioventus in Review of Strategic Alternatives - Latham & Watkins LLP
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Bioventus Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Bioventus (BVS) Drops 8.9% to $13.9: Key Support Tested After Sharp SelloffCall Flow Alert - dars.gov.et
Bioventus (BVS) Stock Jumps On Profit Strength As Growth Risks Remain - simplywall.st
Bioventus earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Bioventus Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:BVS) 2026-08-05 - Seeking Alpha
Bioventus Inc (BVS) (Q2 2026) Earnings Call Highlights: Strategic Review and Strong HA Growth ... - Yahoo Finance
Earnings call transcript: Bioventus posts Q2 2026 EPS beat, shares slip premarket - Investing.com Nigeria
Bioventus (NASDAQ:BVS) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bioventus Inc. Q2 2026 Earnings: Strong Revenue Growth, Net Income, and Financial Highlights - Minichart
Bioventus Inc. Reports Q2 2026 Results and Strategic Review in Latest 10-Q Filing - Kalkine Media
Bioventus Q2 Earnings Call Highlights - MarketBeat
Bioventus Fiscal Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Reaffirmed - marketscreener.com
Bioventus Reaffirms Earnings Guidance for the for the Twelve Months Ending December 31, 2026 - marketscreener.com
Bioventus Stock (BVS) Opinions on Strategic Review Announcement - Quiver Quantitative
Transcript : Bioventus Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com
Bioventus Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Bioventus (NASDAQ:BVS) Releases FY 2026 Earnings Guidance - MarketBeat
Bioventus Q2 2026 Earnings Call Transcript - MarketBeat
Bioventus (BVS) Q2 Earnings Meet Estimates - Yahoo Finance
(BVS) Bioventus Expects 2026 Adjusted EPS Range $0.75$0.79, vs. FactSet Est of $0.78 - marketscreener.com
(BVS) Bioventus Expects Full Year 2026 Revenue Range 600M-$610M, vs. FactSet Est of $605.3M - marketscreener.com
Earnings Flash (BVS) Bioventus Inc. Reports Q2 Revenue $153.2M, vs. FactSet Est of $155.4M - marketscreener.com
Earnings Flash (BVS) Bioventus Inc. Posts Q2 Adjusted EPS $0.22 per Share, vs. FactSet Est of $0.22 - marketscreener.com
Bioventus Inc. 2026: Revenue $153.21M, EPS $0.47— 10-Q Summary - TradingView
Bioventus Q2 Revenue Rises 4% as Strategic Review Begins - Quiver Quantitative
Bioventus Reports Q2 2026 Revenue Growth and Initiates Review of Strategic Alternatives - Quiver Quantitative
Bioventus Q2 revenue misses estimates on surgical solutions decline - TradingView
Bioventus Reports Second Quarter Financial Results - The Manila Times
BRIEF-Bioventus Q2 Adjusted EBITDA USD 35.3 Million - TradingView
Bioventus Starts Review After Unsolicited Acquisition Proposal - Stock Titan
Bioventus Reports Q2 2026 Earnings and Initiates Strategic Alternatives Review - Kalkine Media
Bioventus Shareholder Notice - TMX Newsfile
Bioventus Deadline Alert - TMX Newsfile
Bioventus earnings up next: Can new pain devices fuel growth? By Investing.com - Investing.com India
Responsive Playbooks and the BVS Inflection - Stock Traders Daily
Bioventus (NASDAQ:BVS) Sets New 12-Month HighHere's What Happened - marketbeat.com
Bioventus Inc expected to post earnings of 22 cents a shareEarnings Preview - TradingView
Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026 - The Manila Times
Bioventus Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Bioventus (NASDAQ:BVS) Hits New 12-Month HighStill a Buy? - MarketBeat
Eversept Partners LP Lowers Stake in Bioventus Inc. $BVS - MarketBeat
315,018 Shares in Bioventus Inc. $BVS Bought by Engine Capital Management LP - MarketBeat
BlackRock (BVS) discloses 3.4M-share, 5.02% passive stake in Bioventus - Stock Titan
Bioventus Inc (BVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bioventus Inc (BVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
BVS|Bioventus Inc|Price:12.460|Chg%:+0.660 - TradingKey
2.43%
자본화:
|
볼륨(24시간):